Lorus Therapeutics completes C$25 million offering of common shares

On April 10, 2014, Lorus Therapeutics Inc. (Lorus) announced the completion of its previously announced public offering of 50,000,000 common shares at a price of C$0.50 per offered share, for aggregate gross proceeds of C$25 million.

The offering, announced on March 26, 2014, was sold to a syndicate of underwriters led by RBC Capital Markets and which included Roth Capital Partners and Cormark Securities Inc. The underwriters were granted an over-allotment option to purchase up to 7,500,000 additional common shares, which was partially exercised for additional gross proceeds of C$3.25 million.

Lorus is a clinical-stage biotechnology company with a commitment to discovering and developing targeted therapies addressing unmet medical needs in oncology.

Further information can be found on The Wall Street Journal's website.